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A b s t r a c t
We hereby report a case of a 10-year-old girl in whom neurosurgery was performed for cerebellar vermis medullo-
blastoma in April 2000. After resection the patient underwent chemotherapy followed by radiotherapy, receiving 
53.07 Gy to posterior fossa and 35.07 Gy to the rest of the craniospinal axis. In 2012, she was diagnosed with 
anaplastic astrocytoma, which was located within the high-dose region. Surgical resection of the tumour was per-
formed. Postoperatively, the patient received radiation therapy (50.4 Gy) with concurrent temozolomide, followed 
by 6 cycles of adjuvant temozolomide. Five years after the diagnosis of anaplastic astrocytoma, the patient remains 
asymptomatic.
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Introduction
In 1945, at the Memorial Hospital for Cancer 
and Allied Diseases (nowadays called Memorial 
Sloan-Kettering Cancer Center), Bradley Coley ampu-
tated the lower leg of a 22-year-old man diagnosed 
with tibial sarcoma. Eight years earlier the patient 
had been treated with radium because of fibrous 
dysplasia found radiologically. The dose delivered to 
the bone was 15.5 Gy [4]. Three years later, in the 
publication coming from the same institution, Cah-
an et al. described 11 cases of bone sarcomas (locat-
ed in the ribs, sternum and clavicle), which occurred 
in patients irradiated postoperatively for breast can-
cer. The authors referred to them as second radia-
tion-induced cancer – SRIC and pointed out four 
essential criteria for their diagnosis: previous irradi-
ation, latency period of several years, location of the 
neoplasm within the irradiated area, and histological 
proof of malignancy [5]. Until now, the dose needed 
to initiate carcinogenesis has not been established 
unequivocally. The results of meta-analyses includ-
ing over 3000 patients diagnosed with SRIC revealed 
a linear correlation between the total radiation dose 
and the frequency of malignancies. The majority of 
SRIC were diagnosed in the proximity of tissues, 
which had received doses of 5 to 50 Gy [3,33]. 
Postoperative radiation therapy is an integral 
part of combined treatment of central nervous sys-
tem tumours. Improving treatment results lead to 
prolongation of survival, which thus results in an 
increasing number of secondary brain malignan-
cies. Malignant gliomas (radiation-induced malig-
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nant gliomas – RIMG) comprise more than a half of 
these neoplasms. The medium latency period varies 
between 9 and 19 years according to the literature 
[6,9,23,26,32]. We describe a case of secondary ana-
plastic astrocytoma which occurred 10 years after 
cerebro-spinal irradiation performed because of cer-
ebellar medulloblastoma in a 10-year-old child.
Case report
In April 2000, a ten-year-old girl was admitted to 
the Surgery Department of the Children’s Universi-
ty Hospital in Cracow, presenting with a history of 
2 months of intensifying headaches in the occipital 
region, nausea, vomiting and nystagmus. Diagnostic 
computed tomography (CT) and magnetic resonance 
imaging (MRI) visualised a tumour of the cerebellar 
vermis with a  diameter of 8 cm. The tumour was 
excised totally with suboccipital craniectomy on 
20 April 2000. The histological examination revealed 
a  highly cellular tumour formed by small, uniform 
cells with only thin rims of cytoplasm, exceptional-
ly rarely creating rosette-like structures but mostly 
crowded in compact featureless areas (Fig. 1). 
Focally some glial fibrillary acidic protein (GFAP) 
and synaptophysin immunopositivity was observed. 
As a result, the diagnosis of medulloblastoma – “clas-
sical” variant was established. Cerebrospinal fluid 
was free from neoplastic cells. The patient received 
4 cycles of chemotherapy (SIOP – vincristine, etopo-
side, cyclofosfamide). Systemic treatment ended on 
21 August 2000. From 6 September to 20 October 
2000, the patient received adjuvant irradiation. At 
the first step, a dose of 35.07 Gy in 21 fractions to 
the neuraxis was given. Subsequently, additional 
18 Gy in 10 fractions to the posterior cranial fossa 
were given, resulting in the total dose of 53.07 Gy in 
this area. In July 2012, 12 years after the diagnosis 
of cerebellar medulloblastoma, at the age of 22, the 
patient was admitted to an emergency department 
because of an onset of seizures. MRI was performed 
and showed a  tumour measuring 27×22×19 mm, 
located at the border of the left parietal and occipi-
tal lobe, and characterized with malignant features 
including heterogeneity of enhancement, digitate 
oedema, and mass effect (Fig. 2). 
The patient was admitted to the Neurosurgery 
Department of the University Hospital in Cracow, 
where on 18 July 2012, a macroscopic resection of 
the tumour was performed. The histopathological 
examination revealed an anaplastic tumour of astro-
cytic type (immunopositivity to GFAP). Tumour cells 
were mostly of small or medium size, polymorphic 
and relatively loosely scattered, but somewhat more 
densely aggregated around numerous vessels, how-
ever, not in a  “radiating”, rosette-like arrangement 
(Fig. 3A). Immunohistochemistry using a  mouse 
monoclonal antibody targeting the IDH1 R132H 
mutation has given a negative result.
There were numerous mitoses and conspicuously 
high Ki67 labelling index of 20% was noted (Fig. 3B). 
Some scattered features of cell necrosis could be 
seen though without formation of palisades. Conse-
quently, a diagnosis of anaplastic astrocytoma WHO 
III was adopted. From 10 September to 23 October 
2012 at the Centre of Oncology in Cracow, adjuvant 
chemoradiotherapy was performed. The patient 
was treated with a dose of 50.4 Gy in 28 fractions 
with concurrent temozolomide. Subsequently she 
received 6 cycles of adjuvant temozolomide. At pres-
ent, 5 years after the diagnosis of anaplastic astro-
cytoma, the patient remains asymptomatic in both 
clinical examination and imaging.
Discussion
Radiotherapy is an undisputed element of com-
bined treatment of neoplasms located within the 
central nervous system. It is applied mainly in high-
Fig. 1. Medulloblastoma WHO IV (primary tumour). 
Typical features of a  “classic” variant of medul-
loblastoma. The tumour consists of relatively 
uniform small anaplastic cells with a  high mito-
tic ratio (2 mitoses are seen in the picture), here 
not forming any particular patterns (like rosettes). 
Haematoxylin-eosin.
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grade gliomas in adult patients and germinal tumours 
in children. Radiation therapy, like other methods of 
oncological treatment, is associated with early and 
late adverse effects. A lot of data have been collect-
ed on the most serious late complication, which is 
radionecrosis. Over the last decade, lots of reports 
regarding radiation-induced brain tumours have 
been published. The occurrence of secondary brain 
tumours depends on both institutions’ and authors’ 
experience. According to Paulino et al., a cumulative 
risk of secondary glioma is 1.7% at 10 years, rising to 
2.7% at 15 years [23]. For over 70% of patients after 
neuraxis irradiation, who are diagnosed with a sec-
ondary tumour, the latency period does not exceed 
10 years; however, Hamasaki describes a  case, in 
which the latency period was 35 years [9,12,19]. 
Kamide et al. report a  case of a 5-year-old patient 
diagnosed with medulloblastoma, treated with sur-
gery for high-grade glioma and meningioma after 29 
years. Both lesions were located in the cerebellum, 
Fig. 2. T1-weighted contrast-enhanced axial and sagittal images showing heterogeneously enhancing tumour 
at the border of the left parietal and occipital lobe (A, B). T2-weighted image demonstrates the same lesion 
with digitate oedema and mass effect (C, D).
A B
C D
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Fig. 3. Secondary tumour diagnosed as anaplastic astrocytoma WHO III. The tumour shows moderate cellu-
larity and quite conspicuous perivascular arrangement of tumour cells (haematoxylin-eosin) (A) and notice-
able mitotic activity with a high Ki67 labelling index of 20% (immunohistochemistry) (B).
thus in the high-dose region [14]. According to the 
literature, RIMG occur in the areas irradiated with 
a minimum dose of 30 Gy [10,17,25,34]. Table I pres-
ents cases of radiation-induced gliomas following 
treatment of medulloblastoma.
Van Calenbergh et al. define basic criteria of 
radiation-induced brain tumour: different histo-
pathological features (not only higher grade), loca-
tion in the irradiated area, latency period of several 
years (a minimum interval has not been determined 
yet), excluding tumours in patients with syndromes 
known to present with multiple neoplasms (e.g. 
neurofibromatoses) [30]. Our case meets all these 
criteria: primary neoplasm – medulloblastoma, 
the secondary one – anaplastic astrocytoma (the 
above-described astrocytoma apparently shows no 
IDH-1R132H mutation, at least tested by immuno-
histochemistry), development in the region irradiat-
ed with a  dose of 35.07 Gy and latency period of 
10 years. Although in our case, glioma was ultimate-
ly diagnosed as grade III astrocytoma, we are aware 
that to some extent its morphology may resemble 
pilomyxoid astrocytoma (which is grade II). Howev-
er, this resemblance is only due to loose cellularity 
of the tumour and oedema. The tumour was devoid 
of any true “myxoid” features and although tumour 
cells were denser around vessels, no typical “radi-
ating” rosette-like arrangements around vessels 
(quite characteristic in pilomyxoid astrocytoma) 
were noted and also neuroimaging features were 
not typical for pilomyxoid astrocytoma. Secondary 
gliomas may have different morphology and show 
a  broad spectrum regarding their aggressiveness, 
including a high as well as a low grade and the rela-
tion between histopathology and clinical behaviour 
in secondary gliomas differs from what is observed 
in primary tumours [13,16,35]. In our case frequent 
mitoses and especially high Ki67 labelling index of 
20% (Fig. 3B) pointed out to a rather truly aggressive 
course and this led to diagnosis of grade III astrocy-
toma. What additionally corroborated with neuroim-
aging features of grade III tumour was heterogeneity 
of enhancement, digitate oedema, and mass effect.
Standard treatment of primary high-grade glio-
mas consists of postoperative radiotherapy to a total 
dose of 60 Gy in 30 fractions given concurrently with 
temozolomide and followed by 6 cycles of temozolo-
mide alone. Repeated irradiation of previously irradi-
ated area seems controversial, thus in many institu-
tions it is not performed [22]. The treatment of RIMG 
should take into account the dose delivered during 
the first radiotherapy, the irradiated volume and the 
latency period. The decision concerning repeated 
radiotherapy should be made taking these variables 
into account. Keeping in mind that medium latency 
period between the first and the repeated treatment 
is 9 years and relying on previous experience, we 
estimate that delivering the dose of 50-55 Gy con-
currently with chemotherapy is safe [1,2,8,28,31].
Paulino et al. reviewed the literature from 1960 to 
2005, finding 92 patients diagnosed with RIMG. The 
majority of patients (73%) were under 19 years old 
A B
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at the moment of diagnosis. The median time from 
irradiation to the occurrence of the secondary tumour 
was 8.75 years (range: 2.5 to 61 years) and was 
dependent neither on gender nor on age. There was 
also no difference in the latency period dependent 
on the irradiation dose and other methods of initial 
treatment. The authors noticed that in the case of 
neuraxis or whole brain irradiation, the latency peri-
od was shorter (median period of 7.1 years) compar-
ing to local irradiation (median period of 10.2 years, 
p = 0.0350). Glioblastoma was found in 75% of cas-
es of secondary tumours and anaplastic astrocytoma 
was diagnosed in the other 25% of cases. Table II 
presents different treatment modalities.
Table I. Radiation-induced gliomas following treatment of medulloblastoma
No. Author Age [years]/
Sex 
Total dose
(brain) [Gy]
Total dose 
(posterior cranial 
fossa) [Gy]
Chemotherapy Latency 
period 
[years]
Radiation-induced 
high-grade glioma
1 Kleriga [15] (1978) 0.8/M 50 – 11 High-grade glioma, 
cerebellum
2 Pearl [22] (1980) 5/M 30 +10 13 GBM, parietal lobe
3 Cohen [7] (1981) 4/K 35 +10 14 High-grade glioma, 
frontal lobe
4 Schmidbauer [27] 
(1987)
13/M 60 – Vincristine
Lomustine
6 GBM, 
cerebellum
5 Safneck [24] 
(1992) 
2/M 44 +10 11 AA, 
optic nerve
6 Osumi [20] (1994) 14/K 50 – Vincristine
Lomustine
9 High-grade glioma, 
cerebellum
7 Grabb [11] (1996) 39/K 42.5 +11.9 17 AA, cervical spinal 
cord
8 Furuta [9] (1998) 8/M 40 +15 15 High-grade glioma, 
cerebellum
9 Van Calenbergh 
[30] (1999)
2/M 40 +10 15 AA, parieto-occipital 
region
10 Strojan [29] 
(2000)
10/K 30 +29.5 34 Pilocytic glioma, 
cerebellar vermis
11 Nakamizo [19] 
(2001)
11/M 30 +24 Methotrexate 
Cytarabine
9 High-grade glioma, 
cerebellum
12 Nakamizo [19] 
(2001)
18/K 30 +20 9 High-grade glioma, 
cerebellum
13 Malde [18] (2003) 13/K 35 +20 Vincristine
Lomustine
8 Gliosarcoma, 
fronto-parietal 
region
14 Salvati [26] (2003) 40/M 30 +15 11 GBM, 
parietal lobe
15 Yang [34] (2005) 5/M 36 +20 10 GBM,
cerebellum
16 Hope [13] (2006) 15/M 40 +14 23 AA, cerebellum
17 Gessi [10] (2008) 7/M 20.8 +39.8 8 GBM, cerebellum
18 Hamasaki [12] 
(2010) 
5/M 20.8 – 35 GBM,  
cerebellum
19 Kamide [14] (2010) 5/M 15 +39 29 High grade glioma, 
cerebellum
20 Our case 10/K 35.07 +18 Vincristine
Etoposide
Cyclofosfamide
12 AA, 
cerebellum
M – male, F – female, GBM – glioblastoma multiforme, AA – anaplastic astrocytoma
85Folia Neuropathologica 2019; 57/1
Radiation-induced anaplastic astrocytoma
Median survival for the whole group was 11 
months. Two-year overall survival was 13%. For the 
group of 35 patients treated with radiation therapy 
(median total dose 50 Gy, range from 30 to 76 Gy), 
the median survival was 13 months and 2-year over-
all survival was 20.5%, compared with 8 months and 
3% for those who did not receive repeated irradiation. 
The difference in survival was statistically significant 
(p = 0.0009). Better prognosis was related to histol-
ogy of anaplastic astrocytoma. Two-year overall sur-
vival was 30.3% for those diagnosed with anaplastic 
astrocytoma and 7.3% for patients diagnosed with 
glioblastoma (p = 0.0013). Acute toxicity of reirradia-
tion was low. Episodes of brain oedema were treated 
with steroids, allowing completion of treatment. Seri-
ous late toxicity, e.g. brain radionecrosis, was seen in 
2% of patients [1,2,8,31]. The data obtained suggest 
that reirradiation is the proper treatment option for 
patients diagnosed with RIMG. Neither surgery nor 
chemotherapy correlated with improvement in sur-
vival (p = 0.164, p = 0.536, respectively). 
Conclusions
According to the literature and our own expe-
rience, concurrent chemoradiation is an effective 
treatment method for RIMG, leading to results com-
parable to treatment of primary high-grade gliomas. 
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